These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15850984)

  • 1. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
    Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C
    Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
    Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
    Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
    Watts RE; Siegel M; Khosla C
    J Med Chem; 2006 Dec; 49(25):7493-501. PubMed ID: 17149878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue transglutaminase inhibition.
    Keillor JW
    Chem Biol; 2005 Apr; 12(4):410-2. PubMed ID: 15850975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.
    Klöck C; Herrera Z; Albertelli M; Khosla C
    J Med Chem; 2014 Nov; 57(21):9042-64. PubMed ID: 25333388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.
    Dafik L; Khosla C
    Chem Biol; 2011 Jan; 18(1):58-66. PubMed ID: 21276939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinnamoyl inhibitors of tissue transglutaminase.
    Pardin C; Pelletier JN; Lubell WD; Keillor JW
    J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors.
    Schaertl S; Prime M; Wityak J; Dominguez C; Munoz-Sanjuan I; Pacifici RE; Courtney S; Scheel A; Macdonald D
    J Biomol Screen; 2010 Jun; 15(5):478-87. PubMed ID: 20395409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
    Hausch F; Halttunen T; Mäki M; Khosla C
    Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
    Song M; Hwang H; Im CY; Kim SY
    J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.
    Yuan L; Choi K; Khosla C; Zheng X; Higashikubo R; Chicoine MR; Rich KM
    Mol Cancer Ther; 2005 Sep; 4(9):1293-302. PubMed ID: 16170020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected role of surface transglutaminase type II in celiac disease.
    Maiuri L; Ciacci C; Ricciardelli I; Vacca L; Raia V; Rispo A; Griffin M; Issekutz T; Quaratino S; Londei M
    Gastroenterology; 2005 Nov; 129(5):1400-13. PubMed ID: 16285941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening.
    Chabot N; Moreau S; Mulani A; Moreau P; Keillor JW
    Chem Biol; 2010 Oct; 17(10):1143-50. PubMed ID: 21035737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
    Mehta K; Kumar A; Kim HI
    Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
    Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
    Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
    Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
    Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
    Grosso H; Mouradian MM
    Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.
    Pardin C; Roy I; Lubell WD; Keillor JW
    Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.